Ackrell Capital Cannabis Investment Report – Regulatory Overview (Dec 2017)

Ackrell Capital Cannabis Investment Report – Regulatory Overview (Dec 2017) The passage is a generic regulatory summary of cannabis‑related products and FDA approval processes. It contains no specific actors, transactions, dates, or allegations that could be pursued as an investigative lead. Key insights: Defines how cannabis products may be classified under the FD&C Act.; Outlines FDA drug approval steps (IND, clinical trials, NDA).; Mentions Ackrell Capital, LLC as the report author.